Abstract. Imaging of expression of human epidermal growth factor receptor type 2 (HER2) in breast carcinomas may help to select patients eligible for trastuzumab therapy. The Affibody molecule Z HER2:342 is a small (7-kDa) non-immunoglobulin affinity protein, which binds to HER2 with a picomolar affinity. Previously, a benzyl-DTPA conjugate of Z HER2:342 was labeled with 111 In and demonstrated good targeting in murine xenografts. We considered that the use of the macrocyclic chelator DOTA could increase the label stability and enhance a choice of nuclides, which could be used as a label for Z HER2:342 .
Introduction
Progress in tumor biology has helped to identify a number of receptors, the aberrant expression of which is essential for malignant transformation. Mitogenic signaling of these receptors makes it possible for the tumors to escape proliferation control. One of these receptors is the human epidermal growth factor receptor type 2 (HER2), a member of the transmembrane tyrosine kinase receptor family. According to the contemporary paradigm, HER2 is an orphan receptor which has no ligand. Signaling occurs by heterodimerisation with other receptors, especially HER3, and increases the mitotic signal of these receptors (1). HER2 is not expressed in normal tissues, or its expression is low. Among malignant tumors, expression of HER2 was detected in 25-30% of breast and ovarian carcinomas (2, 3) and in 80% of bladder carcinomas (4) . The disruption of signaling of HER2 is considered as a promising way of treating malignant tumors. Such strategies include the use of monoclonal antibodies, for example trastuzumab (5) and pertuzumab (6) or degradation of HER2 expression (7) . The humanized monoclonal antibody trastuzumab has confirmed clinical efficacy for treatment of breast cancer and has been accepted for routine clinical use (8) . Apparently, such therapy can be efficiently used only for patients with tumors expressing HER2. For this reason, determining the HER2 status in each case of breast cancer is recommended both in the US and in Europe (9, 10) . Detection of HER2 status might be helpful also for the monitoring of anti-HER2 therapy (11) . Taking into account that biopsy samples can produce false-negative results, and that the metastases of HER2-negative tumors can express HER2 (12) , a development of efficient radionuclide methods for visualization of HER2 expression in vivo is desirable.
Earlier approaches to use nuclear medicine for detection of HER2 expression for selection of patients eligible for trastuzumab treatment have been associated with the use of radiolabeled trastuzumab. Behr and co-workers (13) demonstrated that 111 In-labeled trastuzumab can help to select patients responding to antibody treatment, as well as predict cardiotoxicity. However, a later study (14) showed that only 45% of the tumors were detected by 111 In-trastuzumab. The lack of sensitivity could be explained by the low contrast, which is typical for intact immunoglobulins, characterized by slow tumor penetration and slow blood clearance. Size reduction of tumor-targeting proteins improves these parameters, and radiolabeled (Fab') 2 (11, 15) , Fab (16) and singlechain Fv (17) fragments of trastuzumab have been obtained and pre-clinically evaluated to improve contrast and facilitate imaging. Further size reduction can be achieved by the use of non-immunoglobulin scaffold-based affinity proteins, which are selected by phage, cell surface or ribosomal display (18) , such as Affibody molecules.
Affibody molecules (19) use the domain scaffold of the immunoglobulin-binding staphylococcal protein A. This 58-amino-acid-long cysteine-free protein provides a robust framework, independent of disulfide bonds for its folding. The small size (~7 kDa in the monomeric and ~15 kDa in the dimeric form) of Affibody molecules enables fast blood clearance and good tumor penetration. Randomization of 13 solvent-accessible surface residues of the protein A domain was used to create a library containing about 3x10 9 members, providing the isolation of high-affinity ligands for virtually any tumor-associated protein target. Phage display was used to select an anti-HER2 Affibody molecule Z HER2:4 , which binds HER2 with an affinity of 50 nM (20, 21) . We have found that the indirectly radioiodinated and radiobrominated dimeric form of Z HER2:4 (affinity of 3 nM) can specifically target HER2-expressing xenografts, providing a tumor-toblood ratio between 2 and 9 at 4 h pi, depending on the labeling methods and the number of prosthetic groups per protein molecule (22) (23) (24) . Affinity maturation of Z HER2:4 provided a new clone, Z HER2:342 , with an affinity of 22 pM (25) . Indirect radioiodination of Z HER2:342 resulted in a tracer with a tumor-to-blood ratio of 37 for SKOV-3 xenografts in mice 4 h pi (25) . Though 123 I possesses excellent imaging and dosimetric properties, indirect radioiodination requires well-trained personnel, and the short half-life of 123 I complicates the logistics. To facilitate clinical implementation of the Z HER2:342 Affibody molecule, we developed a procedure for 111 In labeling of Z HER2:342 conjugated with benzyl-DTPA via a thiourea bond (26) . The use of benzyl-DTPA as a chelator ensured facile labeling permitting kit formulation and provided a tumor-to-blood ratio of 94 in SKOV-3 xenografts 4 h pi.
The selection of a labeling method is always a trade-off between several requirements. We used benzyl-DTPA in a previous study because of the easy and quick labeling at room temperature. Some publications (27, 28) suggest that the use of DOTA derivatives requires heating up to 100˚C for efficient indium labeling, and that labeling at lower temperatures is rather inefficient (29) . On the other hand, the gallium-DTPA complex is not considered to be sufficiently stable in vivo (30) , and the use of PET with 68 Ga-labeled Z HER2:342 for visualization of HER2 would require the use of a macrocyclic chelator. The robust structure of Affibody molecules and quick and accurate refolding after denaturation give an opportunity to use elevated temperatures for labeling. For this reason, we evaluated the labeling of the anti-HER2 Z HER2:342 Affibody molecule using isothiocyanate-benzyl-DOTA. Since different chelators may have a profound influence on the biodistribution of labeled peptides (31) , in vivo tumor targeting using 111 In-benzyl-DTPA-Z HER2:342 and 111 Inbenzyl-DOTA-Z HER2:342 was directly compared in this study.
Materials and methods
The Affibody molecule Z HER2:342 was produced according to Orlova et al (26) , and was provided for this study by Affibody AB (Bromma, Sweden) as a 2.22-mg/ml solution in PBS. Isothiocyanate-benzyl-DOTA was purchased from Macrocyclics (Dallas, TX, USA), and [
111 In]indium chloride from Tyco Healthcare Norden AB (Sweden). Buffers were prepared using common methods from chemicals supplied by Merck (Darmstadt, Germany). Buffers for conjugation and labeling were purified from metal contamination using Chelex 100 resin (Bio-Rad Laboratories, Richmond, CA, USA). The NAP-5 size exclusion columns were from Amersham Biosciences (Uppsala, Sweden). The 111 In-benzyl-DTPA-Z HER2:342 conjugate for the comparative biodistribution experiment was prepared according to the procedure described by Tolmachev et al (26) .
The radioactivity was measured using an automated γ-counter with a 3-inch NaI(Tl) detector (1480 Wizard, Wallac Oy, Turku, Finland). The distribution of radioactivity along the ITLC SG (silica gel impregnated glass fiber sheets for instant thin layer chromatography, Gelman Sciences Inc.) strips was measured on the Cyclone™ Storage Phosphor system and analyzed using the OptiQuant™ image analysis software.
Conjugation and labeling chemistry. The conjugation of isothiocyanate-benzyl-DOTA to the Affibody molecule Z HER2:342 was performed similarly to the method described by Tolmachev et al (26) , using a calculated chelator-to-protein molar ratio of 1:1, 2:1 or 3:1. Briefly, 500 μg of Z HER2:342 was mixed with freshly prepared solution of isothiocyanatebenzyl-DOTA in 0.07 M sodium borate buffer, pH 9.2. The mixture was incubated overnight at 37˚C. The reaction mixture was purified on a NAP-5 size exclusion column with 1 M ammonium acetate buffer, pH 5.5.
The DOTA-coupling efficiency was evaluated by running analytical RP-HPLC of benzyl-DOTA-Z HER2:342 , using a 4.5x150-mm column with a polystyrene/divinylbenzene matrix of 5-μm particles (Amersham Biosciences) at a flow of 1 ml/min and a 20-min elution gradient of 20-50% B (A, 0.1% TFA-H 2 O; B, 0.1% TFA-CH 3 CN). The molecular weights were confirmed by MALDI-TOF-MS.
Real-time biospecific interaction analysis was performed on a Biacore 2000 instrument (Biacore, Uppsala, Sweden) to measure the binding kinetics of the benzyl-DOTA-Z HER2:342 .
The extracellular domain of HER2 (from Professor Gregory Adams, Fox Chase Cancer Center, Philadelphia, PA, USA) and human serum albumin, HSA, (Kabi Vitrum, Stockholm, Sweden) were diluted to 20 μg/ml in 10 mM NaOAc, pH 4.5 and immobilized on a CM5 sensor chip (Biacore, Uppsala, Sweden). The samples were diluted in the running buffer HBS (10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA and 0.005% Surfactant P20, pH 7.4) to 0.3-20 nM and injected at a flow rate of 50 μl/min. HCl (20 mM) was used for surface regeneration.
The labeling was performed at 60˚C. To study the labeling kinetics, a 40-μg conjugate was mixed with 40 MBq 111 In and incubated for 60 min. The experiment was performed in triplicate. At pre-determined points of time (5, 15, 30 and 60 min), a sample of 0.5 μl was taken and analyzed using ITLC with 0.2 M citric acid.
When the labeling procedure was established, a 15-minlong labeling was used. In some cases, e.g. for biodistribution experiments, the buffer was exchanged by sterile PBS using a NAP-5 column. For cell studies, the reaction mixture was diluted with PBS.
For a label stability test, two samples of benzyl-DOTA-Z HER2:342 were labeled with 111 In and 5-μl samples were mixed either with 62 μl of PBS or with 62 μl of sodium salt of EDTA (20 mg/ml in PBS, 10,000-fold molar excess). The samples were incubated at room temperature. At pre-determined points of time, 1, 3 and 24 h, the samples were analyzed using ITLC.
Cell binding and retention studies. The HER2-expressing ovarian carcinoma cell line SKOV-3 and the breast carcinoma cell line BT474 (both from ATCC) were used for the binding specificity test. A labeled conjugate (7 ng) was added to two groups of three Petri dishes (5x10 5 cells per dish). One group of dishes in each experiment was presaturated with a 1,000-fold excess of non-labeled Affibody. The cells were incubated with labeled conjugate for 1 h at 37˚C, and the incubation media was collected. The cell dishes were washed and treated with 0.5 ml trypsin-EDTA solution (0.25% trypsin, 0.02% EDTA in buffer; Flow Irvine, UK). When the cells were detached, 0.5 ml complete medium was added to each dish, and the cells were re-suspended for radioactivity measurement.
The cellular retention of radioactivity after interrupted incubation was studied according to Tolmachev et al (26) . Briefly, culture dishes were incubated for 2 h with culture medium containing 7 ng 111 In-benzyl-DOTA-Z HER2:342 . The dishes were then washed and incubated at 37˚C with fresh complete media. At pre-determined points of time the incubation media was collected from the 3 culture dishes, and the cells were detached from the culture dishes by trypsin treatment, as described above. The radioactivity associated with the cells and the culture media was measured. The fraction of the initial cell-associated radioactivity was analyzed as a function of time.
Biodistribution studies. The animal studies were approved by the local Ethics Committee for Animal Research. In all the biodistribution studies, the mice were euthanized with an intraperitoneal injection of Ketalar-Rompun solution. The mice were exsanguinated by heart puncture. Blood and organ samples were collected and weighed, and their radioactivity was recorded using an automatic γ-counter. To evaluate the degree of hepatobiliary excretion, the radioactivity in the entire gastrointestinal tract with its content was measured and expressed as % IA per whole sample. The radioactivity in the carcass was evaluated as well and presented as % IA per whole sample. Tissue uptake values were calculated as percent of injected activity per gram tissue (% IA/g).
Biodistribution in immunocompetent NMRI mice was performed on 12 mice that were sc injected with 50 kBq 111 In-benzyl-DOTA-Z HER2:342 (protein dose 1 μg). At 1, 4 and 24 h pi, a group of 4 animals was euthanized and dissected.
The LS174T cell line was used in biodistribution experiments on tumor-bearing mice. According to Milenic and co-authors (32, 33) , this cell line possesses low but uniform expression of HER2 and may be a good model to demonstrate the sensitivity of Z HER2:342 in detection of lowlevel antigen expression. Female outbred Balb/c nu/nu mice were sc injected with one million LS174T cells in the hind leg 3 weeks before the experiment.
Twelve Balb/c nu/nu mice with LS174T xenografts were randomly divided into 3 groups of 4 animals each. One group was sc injected in the neck area with 475 μg of non-labeled Z HER2:342 in PBS. One hour later, 2 groups of mice (1 blocked and 1 non-blocked) were sc injected with 111 In-benzyl-DOTA-Z HER2:342 at a protein dose of 1 μg (~100 kBq) in 100 μl PBS. Additionally, 1 group of mice was injected with the same amount of 111 In-benzyl-DTPA-Z HER2:342 to compare the tumor-targeting properties of the conjugates. At 4 h pi the mice were euthanized and dissected.
γ-camera imaging. Female outbred Balb/c nu/nu mice were sc injected with 10 7 SKOV-3 cells in the hind leg 8 weeks before the experiment. At the time of the imaging, the tumors were ~0.5-0.8 cm 3 . Two animals were injected with 3 MBq (5 μg) 111 In-benzyl-DOTA-Z HER2:342 in the tail vein. The imaging was performed 4 h pi using a Siemens e.CAM γ-camera (Siemens Medical Systems) equipped with an MEGP collimator at the Department of Nuclear Medicine, Uppsala University Hospital. Static images (10 min, 550,000 counts), obtained with a zoom factor of 3.2, were digitally stored in a 256x256 matrix. The pixel size was 2.4 mm. The scintigraphic results were evaluated visually and analyzed quantitatively using Hermes software (Nuclear Diagnostics, Stockholm, Sweden). The quantitative analysis was performed by drawing equal regions of interest (ROI) over the tumor and contralateral thigh, as well as ROI over the kidneys and upper abdomen (liver). Tumor-to-non-tumor ratios were calculated based on counts per pixel.
Results
Conjugation and labeling chemistry. Data of the LC-MS analysis suggested that a single chelator was attached to 59% of the protein molecules, while 15% of the protein remained unconjugated when a 3:1 chelator to protein ratio was used for coupling. Biospecific interaction analysis showed that the binding affinity was somewhat reduced in comparison with non-conjugated Z HER2:342 but still in the subnanomolar range.
The labeling kinetics was fast; even a 5-min-long reaction at 60˚C provided a labeling yield of >97%, with only a minor increase when the labeling was prolonged up to 60 min.
The radiolabeled conjugate retained its stability in PBS for at least 3 h (95.7±0.2% of 111 In associated with Affibody conjugate at a 3-h and 94±1% at a 24-h incubation). The stability at a large molar excess of EDTA confirmed that 111 In was attached via a stable DOTA chelate and not by an occasional combination of amino acids with weak chelating capacity (95.05±0.05 and 89.6±0.4% at a 3-and 24-h incubation, respectively).
Cell binding and retention studies. The specificity of 111 Inbenzyl-DOTA-Z HER2:342 binding to living HER2-expressing cells was controlled using the ovarian carcinoma cell line SKOV-3 and the breast carcinoma cell line BT474. The addition of a large excess of non-labeled Z HER2:342 caused a substantial, 50-to 80-fold decrease in the attachment of radioactivity to cells in both cell lines (18±1 vs. 0.4±0.1% added radioactivity associated with cells for BT474 and 9.0±0.6 vs. 0.11±0.08% for SKOV-3, p<0.0001). This showed the saturable nature of 111 In-benzyl-DOTA-Z HER2:342 binding and indicated that the binding was receptor specific.
The retention pattern of 111 In radioactivity after the interrupted incubation of 111 In-benzyl-DOTA-Z HER2:342 with SKOV-3 is shown in Fig. 1 . Generally, it is similar to the curve obtained previously for 111 In-benzyl-DTPA-Z HER2:342 (26) . The curve is characterized by two segments. An initial drop of radioactivity during the first 4 h after interrupted incubation was followed by a relatively constant amount of cell-associated 111 In. This curve shape might be explained in the following way. Internalization of bound 111 In-benzyl-DOTA-Z HER2:342 seems to be relatively slow, and, after change of culture medium, a substantial part of the conjugate was dissociated in non-degraded form. At the same time, a part of the conjugate was internalized, and this made the cell association of radioactivity practically irreversible due to the residualizing properties of the 111 In label. Note that the level of the plateau is lower for 111 In-benzyl-DOTA-Z HER2:342 (38-40%) than was reported for 111 In-benzyl-DTPA-Z HER2:342 (46-52%), which correlates well with the lower affinity of 111 Inbenzyl-DOTA-Z HER2:342 . An internalization assay could be helpful towards a more accurate interpretation. However, as we pointed out previously (26) part of labeled Z HER2:342 , independently of the label, always binds to HER2-expressing cells irreversibly, and can be removed neither by acid wash nor by displacement by a large excess of non-labeled Z HER2:342 . Figure 1 . Cell-associated 111 In radioactivity as a function of time after interrupted incubation of SKOV-3 cells with 111 In-benzyl-DTPA-Z HER2:342 . The cell-associated radioactivity at time zero after the interrupted incubation was considered as 100%. Data are the mean ± SD (n=3). Error bars might not be seen because they are smaller than point symbols. Table I . Biodistribution of 111 In-benzyl-DOTA-Z HER2:342 in normal NMRI mice. 
a -----------------------------------------------------------------------------------------------------Radioactivity concentration in organs, % IA/g -----------------------------------------------------------------1 h 4 h 24 h -----------------------------------------------------------------------------------------------------

6.2±0.9 5±1 -----------------------------------------------------------------------------------------------------
a Each data point presents an average from 4 animals ± SD and is expressed as the percent of injected radioactivity per gram organ or tissue. Data are the mean ± SD (n=4).
b A small piece of colon (100-150 mg) was dissected and the uptake was measured; c radioactivity was presented as % IA in the whole gastrointestinal tract with content, except for a small 100-to 150-mg piece of colon.
d The radioactivity in the carcass was presented as % IA.
- ---------------------------------------------------------------------------------------------------- 
For this reason, it is difficult to interpret the results of the internalization test.
Biodistribution studies. A study in normal mice was performed to assess blood and whole body clearance and to identify organs with high uptake of radioactivity. The results are presented in Table I . The conjugate was characterized by quick blood clearance, with 1.1±0.2% IA/g 1 h pi and 0.21±0.04% IA/g 4 h pi. The accumulation of radioactivity in a majority of organs was correlated to the radioactivity concentration in the blood. The radioactivity in the gastrointestinal tract was low, indicating that the hepatobiliary excretion plays a minor role. At the same time, the radioactivity accumulation in the liver had no tendency to decrease throughout the study, indicating that internalization of the residualizing indium-111 label occurred. Still, this accumulation was rather low, < 2% IA/g. The organ with the highest radioactivity accumulation was the kidney. Already at 1 h pi, 44±3% of the injected radioactivity (146±31% IA/g) was accumulated in the kidneys, and there was no significant reduction of kidney radioactivity during the observation period. The radioactivity concentration in the bone was low and constant between 4 and 24 h pi.
The biodistribution of 111 In-benzyl-DOTA-Z HER2:342 in nude mice bearing LS174T xenografts is presented in Fig. 2 as well as the effect of a pre-injection of a large amount of non-labeled Z HER2:342 . Although the HER2 expression in LS174T colon carcinoma cells was rather low, the radioactivity concentration in the tumor (4.4±1.0% IA/g) exceeded the uptake in all organs and tissues, except for the kidneys (232±25% IA/g). The pre-injection of a large amount of nonlabeled Z HER2:342 reduced the tumor uptake 7.7-fold, to 0.6±0.2% IA/g (p<0.0005). The blocking of the tumor uptake indicates its saturability and confirms its receptor-mediated nature. Besides tumors, uptake was significantly (p<0.05) reduced in the lungs, liver and spleen. The magnitude of this reduction was 1.2-1.6 times smaller than the reduction in the tumors.
A comparison of the biodistribution of 111 In-benzyl-DOTA-Z HER2:342 and 111 In-benzyl-DTPA-Z HER2:342 is presented in Fig. 3 . The general pattern of biodistribution was similar for both conjugates, with quick blood clearance, high renal uptake and a tumor uptake exceeding the uptake in normal organs, except the kidneys. The difference between the radioactivity accumulation in the kidneys and the tumors was not statistically significant. However, there was a significant (p<0.01) difference between the accumulation of these two conjugates in the blood, liver, spleen, pancreas, and muscles, where the radioactivity concentration at 4 h after injection of 111 In-benzyl-DOTA-Z HER2:342 was 1.5-2.5 times higher than after injection of 111 In-benzyl-DTPA-Z HER2:342 . A significant difference (p<0.05) in tumor-to-organ ratios was found only for the blood and the liver (Fig. 4) . At this point of time, the tumor-to-blood ratios were 23±5 and 50±14, and the tumorto-liver ratio was 1.5±0.1 and 3.2±0.6 for 111 In-benzyl-DOTA-Z HER2:342 and 111 In-benzyl-DTPA-Z HER2:342 , respectively.
γ-camera imaging. Images acquired 4 h after the administration of the 111 In-benzyl-DOTA-Z HER2:342 to immuno- (Fig. 5) . As predicted from the biodistribution studies described above, the renal route of elimination of the conjugates also led to substantial kidney retention. Tumor-tonon-tumor ratios were (average ± maximum error) 33±7 for contralateral thigh, 0.21±0.01 for the kidneys, and 3.3±0.1 for the liver. The higher tumor-to-non-tumor ratios found in the imaging experiment in comparison to the biodistribution data could be explained by using SKOV-3 xenografts with higher HER2 expression than LS174T.
Discussion
The development of labeling methods for scaffold proteins is a challenging problem. With their size and complexity of structure, Affibody molecules occupy an intermediate position between small peptides and antibody fragments. The labeling chemistry of both these groups has been studied relatively well. In small peptides, a pendant group which is necessary for the attachment of a radionuclide, constitutes an appreciable part of the conjugate and often influences its binding capacity and biodistribution dramatically. At the same time, peptides often allow for rather harsh labeling and purification conditions, such as high temperatures, extreme pH, and the use of lipophilic solvents, which would denature antibodies (34) . The biodistribution and binding properties of antibodies are relatively insensitive to the nature of a pendant group, if the antibody is not overmodified, but sensitive to labeling conditions. The influence of labeling methods on targeting properties of scaffold protein-based targeting agents needs to be studied further before we will be able to implement them in nuclear molecular imaging.
The DOTA chelator provides a very stable labeling with 111 In, 68/67 Ga, and 86 Y due to the kinetical inertness of the chelates. The same inertness necessitates the use of elevated temperatures for chelation, and the literature often reports on labeling at 80-100˚C using long reaction times (28, 35, 36) . In our case, >95% labeling efficiency was obtained within 5 min at a lower temperature, 60˚C. The difference is not easily understood, but might well be due to the fact that the work with robust short peptides did not force other researchers to reduce the labeling time and decrease the labeling temperature. Another explanation might be that the good labeling results were ensured by strict metal-free routines in our laboratory (purification of all buffers by Chelex resin and acid washes of vials). Improvement of DOTA labeling by meticulous implementation of metal-free techniques was observed by other researchers as well (37 (Fig. 2) . The reduction of radioactivity uptake in the lungs, liver and spleen after injection of a blocking amount of non-labeled Z HER2:342 (Fig. 2) indicates that there might be cross-reactivity of Z HER2:342 with the murine counterpart of HER2, which correlates well with our previous observations concerning 111 In-benzyl-DTPA-Z HER2:342 (26) . Still, both unspecific and specific uptake in normal tissues was rather low, which provided a good tumorto-organ ratio even in the case of LS174T xenografts with low HER2 expression (Fig. 4) .
Direct comparison with 111 In-benzyl-DTPA-Z HER2:342 (Fig. 3 ) showed that the use of benzyl-DOTA instead of benzyl-DTPA influenced the overall biodistribution of 111 In-labeled Z HER2:342 . Though the blood clearance remained quick for the benzyl-DOTA conjugate, the radioactivity concentration in the blood was ~2.6 times higher than for the acyclic chelator. The same ratio was found between concentrations of radioactivity in the liver. It is difficult to distinguish between the cause and effect. Both the lower glomerular filtration rate and the larger distribution volume in the liver of 111 In-benzyl-DOTA-Z HER2:342 might have caused the observed biodistribution. Although 111 In-benzyl-DOTA-Z HER2:342 gave an elevated radioactivity concentration in the spleen, pancreas and muscle, only the tumor-to-blood and the tumor-to-liver ratios were significantly lower for this conjugate. Despite the lower affinity, the tumor uptake of 111 In-benzyl-DOTA-Z HER2:342 did not differ significantly from the uptake of 111 Inbenzyl-DTPA-Z HER2:342 . It should be noted that the affinity of the benzyl-DOTA conjugate was still in the subnanomolar range. The radioactivity concentration in bone did not differ between these conjugates, though DTPA is considered a weaker chelator. The blood residence time of the Affibody-DTPA conjugate might be too short to be seriously challenged by the circulating transferrin. Taken together, these data demonstrated that even for a relatively small scaffold protein, such as the Affibody molecule (the molecular weight with the chelator is ~8 kDa), the chelator can influence the biodistribution of the conjugate, and such an influence should be evaluated.
It should be noted that although the tumor-to-non-tumor ratio of 111 In-benzyl-DOTA-Z HER2:342 was lower than that of 111 In-benzyl-DTPA-Z HER2:342 , it was still well suitable for in vivo imaging, as demonstrated by the γ-camera experiment. The SKOV-3 ovarian carcinoma cell line, which was used for the development of xenografts in the imaging study, expresses about 1.2 million HER2s per cell (38) , which matches tumors with 3+ expression of HER2. Such xenografts can be visualized with high contrast. The radioactivity accumulation in the liver was lower than that in the tumor, as seen in Fig. 5 .
The only organ, which had a higher radioactivity accumulation than the tumor, was the kidney. This might complicate imaging of targets located close to the kidneys. On the other hand, the kidney could be well located using SPECT/CT or (with an appropriate nuclide) PET/CT, which excludes misinterpretation of images. For this reason, we do not consider high renal uptake as a serious problem for the introduction of DOTA-Z HER2:342 into clinical practice.
In conclusion, isothiocyanate-benzyl-DOTA was coupled to the anti-HER2 Affibody molecule Z HER2:342 . The obtained conjugate was efficiently labeled with 111 In in relatively mild conditions and preserved its capacity to bind selectively to HER2-expressing cells. 111 In-benzyl-DOTA-Z HER2:342 demonstrated a capacity to specifically target HER2-expressing xenografts in vivo, though providing lower contrast than 111 In-benzyl-DTPA-Z HER2:342 . The results of this study open a path for the investigation of benzyl-DOTA-Z HER2:342 conjugates labeled with positron-emitting radiometals ( 68 Ga, 55 Co and 86 Y) and with radiolanthanides for locoregional therapy.
